Tested HAIC for liver cancer after prior immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed hepatocellular carcinoma (HCC) by pathology (tissue testing).
- Your liver cancer is advanced and cannot be removed or has spread, and there is at least one measurable tumor spot on scans.
- Your liver function is fairly preserved (Child-Pugh class A or B) and any fluid buildup (ascites) is controlled with water pills, with no brain confusion from liver disease.
- You can provide tumor tissue for testing (archived tumor tissue from a previous procedure is allowed).
- Your overall health and blood tests are good enough (bone marrow, kidney, and liver numbers meet the study’s cutoff levels).
- You agree to attend scheduled visits and blood tests, and you use effective birth control during the study and for 4 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a liver-directed chemotherapy (HAIC) plus an immunotherapy (PD-1) before surgery, followed by more immunotherapy after surgery, for people with a specific type of liver cancer that has a high chance of coming back. The goal is to see if this approach can reduce the risk of recurrence.
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
This trial tests a new combination of treatments for intrahepatic cholangiocarcinoma (a bile duct cancer in the liver) that cannot be surgically removed. It combines chemo directly into the liver with two drugs that boost the immune system and block blood vessel growth, hoping to shrink the tumor and help you live longer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.